B. Riley FBR analyst David Buck reiterates a Neutral rating on shares of Corcept Therapeutics with an $11 price target following another short seller report as well as response from the company. Negative commentary from short-seller reports have raised a number of issues, including off-label promotion, bribing physicians through speaker fees or otherwise to prescribe Korlym, questioning the efficacy of Korlym and using the FDA's adverse event reporting database to taint the drug as dangerous, and the possible overstatement of sales from the Veteran's Administration channel, Buck tells investors in an intraday research note. He believes Corcept's response this morning to the allegations is "helpful," but he does not expect the overhang to lift immediately from the shares. The stock in midday trading is up 3%, or 32c, to $10.52.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies... To see the rest of the story go to thefly.com. See Story Here